Eli Lilly’s Zepbound eases obstructive sleep apnea in trials; Biden administration announces new partnership with 50 countries to stifle future pandemics

Taking stock of the drug industry, from the lab to the medicine chest

April 17, 2024 Check out STAT+

Sponsored By

By Ed Silverman Pharmalot Columnist, Senior Writer

Adobe STAT+ | Eli Lilly's Zepbound eases obstructive sleep apnea in trials Eli Lilly reported Wednesday that the GLP-1 drug cut breathing interruptions in obese or overweight patients experiencing the condition. By Elaine Chen Biden administration announces new partnership with 50 countries to stifle future pandemics U.S. government officials will offer support in 50 countries, most of them located in Africa and Asia, to help prevent future outbreaks. By Associated Press STAT+ | Teladoc became a household name under Jason Gorevic. Investors wanted more Gorevic's departure follows a series of missed financial projections, a precipitous decline in Teladoc's stock price, and an uninspired vision for its future. By Mario Aguilar and Mohana Ravindranath

More around STAT

Check out more exclusive coverage with a STAT+ subscription Read premium in-depth biotech, pharma, policy, and life science coverage and analysis with all of our STAT+ articles.

---

Enjoying Pharmalot? Tell us about your experience Continue reading the latest health & science news with the STAT app Download on the App Store or get it on Google Play

STAT, 1 Exchange Place, Boston, MA ©2024, All Rights Reserved. I no longer wish to receive STAT emails

Update Newsletter Preferences     •    Contact Us     •    Advertise with Us     •    View in Browser